CJC-1295 no DAC (Mod GRF 1-29) Parkison’s disease

Parkison’s disease

Mice given NAD+ show increased rates of metabolism and improved lean body mass

GHK-Cu may play a particularly synergistic role due to its overlapping anti-inflammatory properties with both BPC-157 and TB500

In the study

CJC-1295 no DAC (Mod GRF 1-29) Parkison’s diseaseCJC 1295 (no DAC) (Modified GRF) is a truncated peptide analogue of growth hormone releasing hormone (GHRH). First developed in the 1980s, research studies with modGRF have shown it to improve muscle repair and growth, accelerate wound healing, strengthen bones, increase fat burning, and improve metabolism. It may also have beneficial effects on blood sugar regulation and the immune system. Modified GRF (1 29) 2mg Peptide (CJC 1295 Without DAC)